The drug, in this model, is a bridge. Sustained lifestyle change is the other bank.
Across fertility clinics in India, a quiet reordering of reproductive medicine is underway—one that begins not at the moment of conception, but months before it, in the metabolic conditions that shape whether conception is possible at all. GLP-1 receptor agonists, drugs born from diabetes and obesity medicine, are being folded into pre-conception care for women carrying the compounded burdens of PCOS, insulin resistance, and obesity—conditions that afflict tens of millions on the subcontinent. The practice reflects a genuine biological logic, yet it runs ahead of the evidence that would fully justify it, leaving specialists, patients, and the field itself navigating the uncertain space between promising rationale and proven outcome.
- India's fertility clinics are prescribing weekly GLP-1 injections to women with obesity and PCOS before IVF even begins, fundamentally restructuring when and how reproductive care starts.
- The drugs carry real promise—restoring ovulation, improving insulin sensitivity, reducing procedural risk—but fertility-specific data on egg quality and IVF success rates remains thin and still evolving.
- A hard stop rule complicates the approach: patients must discontinue GLP-1 therapy at least two months before conception, risking reversal of metabolic gains if lifestyle changes haven't taken hold.
- Appetite suppression raises a quiet nutritional alarm—women preparing for pregnancy may be depleting folic acid and micronutrients at precisely the moment their bodies need them most.
- Patient demand, driven by social media and celebrity weight-loss narratives, is arriving in consultation rooms faster than clinical evidence can answer it, forcing specialists to manage expectation as much as biology.
- The field is divided not between the careful and the careless, but between those who read early evidence as sufficient for selective use and those who insist the bar for a newer, less-studied drug must be higher.
A woman arrives at a fertility clinic carrying years of metabolic struggle—PCOS, insulin resistance, weight that resists every intervention. Two years ago, she would have been sent away to lose weight on her own before treatment could begin. Now, increasingly, she is not sent away at all. Fertility specialists across India are building what some call a metabolic runway: a structured pre-conception phase, often involving GLP-1 receptor agonists, designed to bring weight, insulin, and hormonal function into order before fertility treatment formally begins.
The biological case is grounded in India's particular burden. Over 100 million people live with type 2 diabetes here. One in five women of reproductive age carries a PCOS diagnosis. Obesity among urban women has climbed sharply, driven by sedentary work, dietary shifts, and a genetic predisposition to insulin resistance that emerges earlier and more aggressively than in many Western populations. These conditions disrupt ovulation, suppress reproductive hormones, and raise miscarriage risk. GLP-1 drugs act on that metabolic cluster at its root, and clinics including Indira IVF, Oasis Fertility, Fortis Hospital, and Gleneagles BGS Hospitals have begun folding them into pre-conception protocols for selected patients—often in collaboration with endocrinologists, with defined targets and timelines.
Not every specialist is persuaded. Dr. Shalini Singh at Ankura Hospital in Hyderabad declines to prescribe semaglutide, citing unknown long-term effects and the availability of established alternatives like metformin. The division in Indian fertility medicine is not between those who value evidence and those who dismiss it—it is between those who read the current evidence as sufficient justification for selective use and those who do not. The prescribing specialists acknowledge that fertility-specific outcome data remains limited. The skeptics argue that enthusiasm and biological rationale are not the same as proof.
The drugs' long half-life creates a practical complication: GLP-1 therapies must be stopped at least two months before conception attempts, given the near-total absence of pregnancy safety data. If the window between stopping and conceiving stretches, metabolic gains can erode—particularly if lifestyle changes have not taken root. Appetite suppression adds another layer of concern. Women eating significantly less while preparing for pregnancy risk depleting folic acid and other micronutrients essential in the earliest weeks after conception, a worry that carries particular weight in a country where anemia is widespread among women of reproductive age.
Demand for these drugs has not waited for clinical consensus. Patients arrive naming specific medications, their expectations shaped by social media and global weight-loss coverage rather than reproductive medicine data. Specialists now counsel the distance between public enthusiasm and clinical evidence as part of the consultation itself. The conversation is beginning to extend to male partners as well—obesity suppresses testosterone and reduces sperm quality, and some specialists see parallel logic in metabolic preparation for both. What GLP-1 therapies ultimately deliver for fertility—in egg quality, embryo viability, and pregnancy success—will depend on trials still running and outcomes still unmeasured. The runway is being built while the destination remains, for now, just out of sight.
A woman walks into a fertility clinic carrying the weight of years—not just her own body, but the accumulated burden of a metabolic condition that makes conception harder. Two years ago, she would have heard the same advice at every appointment: lose weight on your own, then come back. The waiting happened outside the clinic walls. Now, something has shifted. Fertility specialists across India are beginning treatment months before a patient ever enters an IVF cycle, using a class of drugs originally designed for diabetes and obesity—GLP-1 receptor agonists—as part of what they call metabolic preparation or reproductive readiness. The fertility runway, as some specialists describe it, now starts earlier. For some patients, it starts with a weekly injection.
The biological case for this shift is straightforward. India carries a metabolic burden that fertility medicine cannot ignore. More than 100 million people live with type 2 diabetes here, the second-largest affected population globally. One in five women of reproductive age carries a diagnosis of polycystic ovary syndrome. Obesity rates among urban women have climbed sharply over the past decade, driven by sedentary work, dietary changes, and a genetic predisposition to insulin resistance that emerges earlier and more aggressively than in many Western populations. These conditions do not sit in isolation. They disrupt ovulation, suppress reproductive hormones, raise miscarriage risk, and reduce the probability of conception. A specialist treating a woman with obesity, PCOS, and insulin resistance is treating a cluster that sits upstream of fertility treatment itself. GLP-1 drugs work on that cluster at its metabolic root, improving weight and insulin sensitivity in ways that can restore menstrual regularity and ovulation.
Clinics including Indira IVF, Oasis Fertility, Fortis Hospital, and Gleneagles BGS Hospitals have folded these drugs into pre-conception protocols for selected patients. Nitiz Murdia, managing director of Indira IVF, describes a practice that now begins months before a patient enters an IVF cycle, with fertility specialists and often endocrinologists working jointly toward defined metabolic targets and timelines. Women with PCOS who have spent years moving between diet plans, exercise programs, and metformin prescriptions—frustrated by the difficulty of meaningful weight loss—now have another tool. "By improving weight and metabolic health, they can help address factors that negatively impact ovulation and reproductive outcomes," Murdia explains. The runway concept changes how fertility care is sequenced. A woman does not wait outside the clinic until she loses weight independently. She enters a structured phase, managed with a defined endpoint. When she meets her targets, conception planning begins.
But not every specialist agrees the runway is ready. Dr. Shalini Singh, a fertility specialist at Ankura Hospital in Hyderabad, refuses to prescribe semaglutide. "We are not using semaglutide right now because it is a new drug and we need more studies to confirm there are no long-term side effects," she says. "We do not know what the impact will be on these women after ten years." Her position reflects a genuine division in Indian fertility medicine. The prescribing specialists do not dispute that fertility-specific evidence remains limited. They argue that the metabolic rationale is sufficiently robust to justify selective use now, while research matures. The skeptics counter that enthusiasm and early data do not constitute sufficient justification for adopting a newer, less-studied agent when established treatments like metformin already exist. Bariatric surgery, available for decades for severely obese patients, has never become routine in fertility care, Singh notes. She does not believe semaglutide will either. The gap between those two positions is where current practice lives.
Demand for these drugs did not originate in the clinic. It arrived on its own, shaped by social media, celebrity endorsements, and global coverage of GLP-1 therapies for weight loss. Patients now name specific drugs before a doctor raises the subject. "Many patients are now proactively asking about these medications when they seek fertility care," Murdia says. Dr. Manisha Singh, a reproductive medicine specialist at Fortis Hospital in Bengaluru, observes the same shift. Specialists must now counsel patients whose expectations have been shaped by weight-loss headlines rather than reproductive medicine data, managing the distance between public enthusiasm and clinical evidence as part of the consultation itself.
Every prescribing specialist reaches for the same distinction, and it matters because the public narrative consistently blurs it: GLP-1 drugs promote weight loss and improve metabolic health. In women with PCOS, these changes can restore menstrual regularity and ovulation. They reduce procedural risk by lowering body weight before anesthesia and ovarian stimulation. What they do not do, at least not with sufficient evidence, is improve egg quality, embryo quality, or IVF success rates directly. "While some studies suggest improvements in reproductive outcomes, robust evidence for direct improvement in egg quality or IVF success rate is still evolving," says Dr. Annapureddy Kumari, a fertility specialist at Oasis Fertility. The biological rationale is stronger than the outcome data. That gap is the story inside the story.
A practical problem emerges from the drug's long half-life. GLP-1 receptor agonists remain in the body for weeks after the last dose. Given the near-total absence of safety data during pregnancy, every prescribing specialist applies the same rule: discontinue at least two months before attempting conception or embryo transfer. This creates a planning challenge. A woman who responds well to GLP-1 therapy must stop the drug before attempting conception. If the gap between stopping and conceiving stretches, the metabolic gains can erode. "The weight can return after stopping the medication if the patient does not actively change their lifestyle and monitor their metabolic rate," says Dr. Sowmya K N, a consultant obstetrician and gynaecologist at Gleneagles BGS Hospitals. The drug, in this model, is a bridge. Sustained lifestyle change is the other bank, and not every patient reaches it.
What patients fail to consume may matter as much as what they lose. GLP-1 receptor agonists suppress appetite—that is central to how they produce weight loss. But a woman preparing for pregnancy who eats significantly less than before runs a nutritional risk that weight-loss trials do not capture. Dr. Shalini raises this concern directly. "Because of appetite suppression, there can be micronutrient deficiencies in some women, and that may affect fertility later on," she says. Folic acid, essential for neural tube development in the first weeks after conception, is among the nutrients that inadequate food intake depletes. In a country where anemia affects a significant proportion of women of reproductive age, this concern carries particular weight. Whether GLP-1 therapy in pre-conception patients receives consistent nutritional monitoring across every clinic that prescribes it is a question the current evidence does not answer.
The conversation around these drugs and fertility centers almost entirely on women, yet obesity affects male fertility as well. Obesity suppresses testosterone production in men and reduces sperm quality through hormonal and inflammatory pathways. "In men, obesity leads to a decrease in testosterone hormone, so it can be used to correct that as well," says Dr. Srinivasa Varalakshmi Yakasiri, regional medical head at Oasis Fertility. The evidence base for male reproductive benefits is even thinner than it is for women, but the logic runs parallel: improve metabolic health before conception, for both partners, not only the one who carries the pregnancy. The tension this story carries is not between doctors who care about evidence and those who do not. It is between those who read the current evidence as sufficient justification for selective use and those who read it as insufficient. Fertility medicine has traditionally focused on what happens after a couple decides to conceive. GLP-1 therapies are shifting attention to what happens before that moment arrives. Clinics are increasingly building a metabolic runway before pregnancy, constructing a pre-conception phase where weight, insulin, and hormonal function are brought into order before fertility treatment formally begins. Where that runway ultimately leads will depend on evidence that is still being gathered, in trials that are still running, for outcomes that remain, for now, unmeasured.
Notable Quotes
We are not using semaglutide right now because it is a new drug and we need more studies to confirm there are no long-term side effects. We do not know what the impact will be on these women after ten years.— Dr. Shalini Singh, Fertility Specialist, Ankura Hospital
By improving weight and metabolic health, they can help address factors that negatively impact ovulation and reproductive outcomes.— Nitiz Murdia, Managing Director, Indira IVF Hospital
The Hearth Conversation Another angle on the story
Why are fertility clinics suddenly interested in weight-loss drugs? Aren't there other ways to help women prepare for pregnancy?
The metabolic conditions affecting fertility in India—obesity, PCOS, insulin resistance—are widespread and stubborn. Diet and exercise alone work for some women, but many struggle for years without meaningful change. These drugs offer something different: they address the underlying metabolic dysfunction, not just the symptom of weight.
But the source material suggests the evidence for fertility outcomes is weak. Why prescribe something that hasn't been proven to improve pregnancy success?
That's the exact divide among specialists. Some argue the biological logic is sound enough to justify selective use while research catches up. Others say that's exactly backwards—you don't adopt new treatments before you know they work. Both positions have merit.
What happens to a woman who loses weight on these drugs, then has to stop them two months before trying to conceive?
That's the bridge problem. The drug works, but it's temporary. If she hasn't built sustainable lifestyle habits by the time she stops, the weight often returns. She's back where she started, except now she's lost months and the clock is ticking.
I noticed the article mentions nutritional deficiencies. Is that a real concern or theoretical?
It's real enough that specialists are worried. Appetite suppression means women eat less. In a country where many women already struggle with anemia and micronutrient deficiencies, eating significantly less while preparing for pregnancy—when nutrition is critical—creates a genuine risk. But we don't have data on how often this actually happens.
Why is the male fertility angle barely discussed?
Because the entire conversation is built around women's bodies. But obesity affects sperm quality and testosterone in men too. If metabolic optimization matters for fertility, it should matter for both partners. That's barely being explored.
What does the future look like? Will these drugs become standard?
The specialists themselves are cautious about that. They think GLP-1 drugs may become important for selected patients—those with obesity, PCOS, insulin resistance. But they're unlikely to become routine. The evidence will determine that, not enthusiasm. And that evidence is still being written.